KI
ACAD icon

Kula Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Kula Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$220K Buy
+11,706
New +$223K 0.05% 542

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kula Investments's ACAD Position: Q1 2023 in Review

Kula Investments opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2023: 11,706 shares worth $220K. The stake represents 0.05% of the portfolio and ranks #542 among its holdings.

232 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Kula Investments held 11,706 shares of Acadia Pharmaceuticals worth $220K as of Q1 2023.
  • Acadia Pharmaceuticals was a new Kula Investments position in Q1 2023.
  • Acadia Pharmaceuticals made up 0.05% of Kula Investments's portfolio in Q1 2023, its #542 holding.
  • 232 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.